Key Laboratory for Organic Electronics and Information Displays & Institute of Advanced Materials (IAM), Jiangsu National Synergetic Innovation Center for Advanced Materials (SICAM), Nanjing University of Posts & Telecommunications, 9 Wenyuan Road, Nanjing, 210023, China.
Department of Cardiology, Zhongda Hospital, Medical School of Southeast University, 87 Dingjiaqiao, Nanjing, Jiangsu, 210009, China.
Biomaterials. 2019 Oct;219:119393. doi: 10.1016/j.biomaterials.2019.119393. Epub 2019 Jul 27.
Photodynamic therapy (PDT) combined with hypoxia-activated prodrugs to overcome hypoxia environment has been recently explored as a promising clinical modality for cancer therapy. Nevertheless, delivering these two therapeutic agents together to different tumour areas that possess a number of biological barriers remains a considerable challenge. Herein, we used the semiconducting polyelectrolyte-based zwitterionic photosensitizer (PFNS) to modify the surface of upconversion nanoparticles (NPs) and prepare near-infrared (NIR) light-responsive PDT agents (UCNP@PFNS). A pH-sensitive Mn-Ca(PO) (MnCaP) layer was further coated onto UCNP@PFNS with the hypoxia-activated prodrug AQ4N incorporated inside. The final nanocomposites exhibited a diameter of 73 nm with high stability in the blood and a remarkably enhanced permeability and retention (EPR) effect in tumours. Importantly, when these nanoparticles reached the tumour site, the acidic tumour microenvironment (pH 6.5-6.8) decomposed the MnCaP layer, releasing both UCNP@PFNS (30 nm) and AQ4N. The relatively small size of UCNP@PFNS and AQ4N satisfied the different distribution requirements in tumour and achieved a high therapeutic effect, thereby reaching an inhibition rate of as high as 83%. In addition, Mn ions can be released during the decomposition of CaP, leading to a significantly increased magnetic resonance (MR) signal in the tumour site. Overall, we report a nanoparticle guided by MRI and fluorescence imaging possesses of tandem active pattern of PDT and chemotherapy, which is promising for future clinical diagnosis and treatment.
光动力疗法(PDT)与缺氧激活前药相结合,以克服缺氧环境,最近已被探索作为癌症治疗的一种有前途的临床方法。然而,将这两种治疗剂一起递送到具有许多生物屏障的不同肿瘤区域仍然是一个相当大的挑战。在此,我们使用基于半导体聚电解质的两性离子光敏剂(PFNS)修饰上转换纳米颗粒(NPs)的表面,并制备近红外(NIR)光响应 PDT 剂(UCNP@PFNS)。进一步将 pH 敏感的 Mn-Ca(PO)(MnCaP)层涂覆到 UCNP@PFNS 上,其中包含缺氧激活前药 AQ4N。最终的纳米复合材料的直径为 73nm,在血液中具有高稳定性,并在肿瘤中表现出显著增强的渗透性和保留(EPR)效应。重要的是,当这些纳米颗粒到达肿瘤部位时,酸性肿瘤微环境(pH 6.5-6.8)分解 MnCaP 层,释放出 UCNP@PFNS(30nm)和 AQ4N。UCNP@PFNS 和 AQ4N 的相对较小尺寸满足了肿瘤中不同的分布要求,并实现了高治疗效果,从而达到了高达 83%的抑制率。此外,在 CaP 分解过程中可以释放出 Mn 离子,导致肿瘤部位的磁共振(MR)信号显著增加。总之,我们报告了一种由 MRI 和荧光成像引导的纳米颗粒,具有 PDT 和化学治疗的串联主动模式,有望用于未来的临床诊断和治疗。